Ritanserin

Ritanserin
Identifiers
	IUPAC name 6-[2-[4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl]ethyl]-7-methyl-[1,3]thiazolo[2,3-b]pyrimidin-5-one;
CAS Number	87051-43-2;
PubChem CID	5074;
CompTox Dashboard (EPA)	DTXSID9042594 ;
ECHA InfoCard	100.163.772
Chemical and physical data
Formula	C27H25F2N3OS
Molar mass	477.569 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C(=O)N2C=CSC2=N1)CCN3CCC(=C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F)CC3;

Ritanserin is a serotonin antagonist with wide-reaching possibilities for the treatment of many neurological disorders.

When used together with typical antipsychotics in the treatment of schizophrenia is able to decrease negative symptoms and adds some "atypicality" as parkinsonism is slightly decreased.

Possible effects on platelets have also been proposed.^[1]

Pharmacology

Ritanserin is a 5-HT₂ receptor antagonist^[2] (Ki = 0.39 nM). It has anxiolytic effects in vivo.

^ Wagner B, Schneider B, Blöchl-Daum B; et al. (1990). "Effect of ritanserin, a 5-hydroxytryptamine2-receptor antagonist, on platelet function and thrombin generation at the site of plug formation in vivo". Clinical pharmacology and therapeutics. 48 (4): 419–23. PMID 2146058. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
^ Akhondzadeh S, Malek-Hosseini M, Ghoreishi A, Raznahan M, Rezazadeh SA (2008). "Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study". Progress in neuro-psychopharmacology & biological psychiatry. doi:10.1016/j.pnpbp.2008.08.020. PMID 18801405. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.